S. E. Madueño

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis

E. Leray, J. Lechner-Scott, S. Vukusic, 2021, Neurology.

Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study.

V. Meca-Lallana, T. Castillo-Triviño, F. Gascón-Giménez, 2024, Multiple sclerosis and related disorders.